Access to anti-retroviral drugs, male in Somalia

Somalia: Access to anti-retroviral drugs, male was 63.0% in 2024. ◆ Volatile

Latest (2024)
63.0%
Change on year
up 12.5%
World rank
92nd
of 141 countries
All-time high
63.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Somalia, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 0 %2006: 1 %2007: 2 %2008: 5 %2009: 7 %2010: 10 %2011: 12 %2012: 16 %2013: 17 %2014: 20 %2015: 25 %2016: 29 %2017: 33 %2018: 37 %2019: 39 %2020: 43 %2021: 45 %2022: 48 %2023: 56 %2024: 63 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Somalia is 63.0%, measured in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 12.5% on the previous year and up 215.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Somalia peaked at 63.0% in 2024 and was at its lowest, 0.0%, in 2000.

Somalia ranks 92nd of 141 countries on this measure, in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Somalia, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Somalia, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 0.0%
2006 1.0%
2007 2.0% +100.0%
2008 5.0% +150.0%
2009 7.0% +40.0%
2010 10.0% +42.9%
2011 12.0% +20.0%
2012 16.0% +33.3%
2013 17.0% +6.2%
2014 20.0% +17.6%
2015 25.0% +25.0%
2016 29.0% +16.0%
2017 33.0% +13.8%
2018 37.0% +12.1%
2019 39.0% +5.4%
2020 43.0% +10.3%
2021 45.0% +4.7%
2022 48.0% +6.7%
2023 56.0% +16.7%
2024 63.0% +12.5%

Averages by decade

DecadeAverage LowestHighest Years
2000s 1.5% 0.0% 7.0% 10
2010s 23.8% 10.0% 39.0% 10
2020s 51.0% 43.0% 63.0% 5

Countries ranked near Somalia

  1. 92 Bulgaria 63.0% compare
  2. 94 Bhutan 62.0% compare
  3. 94 Guinea-Bissau 62.0% compare
  4. 94 Timor-Leste 62.0% compare

See the full ranking of 160 places →

More gender data for Somalia

All data for Somalia →

Frequently asked questions

What is access to anti-retroviral drugs, male in Somalia?
Access to anti-retroviral drugs, male in Somalia was 63.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Somalia?
The highest recorded value was 63.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Somalia?
The lowest recorded value was 0.0% in 2000.
How does Somalia rank for access to anti-retroviral drugs, male?
Somalia ranks 92nd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Somalia?
Over the last ten years it is up 215.0%. The long-run trend across the full record is volatile.
Where does this Somalia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Somalia. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/somalia-fed-rep/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/somalia-fed-rep/">Access to anti-retroviral drugs, male in Somalia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.